GSC Biological and Pharmaceutical Sciences

eISSN: 2581-3250 CODEN (USA): GBPSC2

Cross Ref DOI: 10.30574/gscbps

Journal homepage: https://gsconlinepress.com/journals/gscbps/

(REVIEW ARTICLE)

Check for updates

Fetal cell-derived bio serum in cosmetic dermatology: Sources, bioactivity, and therapeutic potential

KK Murari, E Balakoti, GVS Praneeth and Swathi Putta *

Department of Pharmacology, Raghu College of Pharmacy, Dakamarri, Visakhapatnam.

GSC Biological and Pharmaceutical Sciences, 2025, 31(01), 182-194

Publication history: Received on 09 March 2025; revised on 14 April 2025; accepted on 16 April 2025

Article DOI: https://doi.org/10.30574/gscbps.2025.31.1.0158

Abstract

The emergence of bioserum derived from fetal cells is revolutionizing regenerative cosmetics by providing a bioactive, cell-free alternative to traditional anti-aging and skin repair treatments. This mini-review examines the scientific foundations, sources, production methods, and applications of bioserum from human fetal tissues, focusing on dermal fibroblasts, mesenchymal stem cells (MSCs), and embryonic stem cell (ESC) derivatives. These bioserums are rich in regenerative biomolecules like growth factors (EGF, FGF, TGF-β), cytokines, and exosomes, which work synergistically to improve dermal rejuvenation and promote scarless wound healing. Conditioned media from fetal dermal fibroblasts and MSCs obtained from the umbilical cord and placenta have gained attention for their efficacy and relatively favorable ethical profiles. In contrast, while ESC-derived bioserum shows strong regenerative potential, it faces ethical and regulatory challenges. The review also discusses production issues, safety concerns, and the commercialization status of fetal bioserum, along with emerging trends like synthetic mimetics and exosome delivery. Despite promising benefits, concerns about standardization, cost, and long-term safety require careful consideration. This article provides an overview for researchers and clinicians interested in the therapeutic potential of fetal cell-derived bioserum in advanced cosmeceutical science.

Keywords: Fetal Cell-Derived Bioserum; Regenerative Cosmetics; Mesenchymal Stem Cells; Conditioned Media; Exosomes; Skin Rejuvenation

1. Introduction

The evolution of modern skincare has undergone a remarkable transformation, pivoting away from harsh synthetic chemicals to embrace bioactive, naturally derived compounds that prioritize both effectiveness and safety (1; 2). Among these groundbreaking innovations, bio serums—biologically active formulations created through natural or advanced biotechnological processes—have surfaced as a crucial category of cosmetic ingredients (3). These serums are celebrated for their exceptional regenerative, anti-aging, and skin-restorative properties (4;5).

Notably, serums derived from fetal cells, including human fetal fibroblasts and stem cell-conditioned media, represent a pioneering frontier in the realms of dermatological and cosmetic biotechnology (6; 7). These sophisticated cell-derived factors are rich in a diverse array of growth signals and regenerative cues that closely mimic the body's natural skin healing mechanisms (8; 9). As a result, they have garnered significant attention from researchers and cosmetic manufacturers alike, eager to explore their potential in crafting innovative skincare solutions that promote vibrant, resilient skin (10;3).

* Corresponding author: Swathi Putta.

2. Historical context and conceptual basis

The exploration of cell-derived components within the realm of cosmetic science has a rich history that spans several decades, originating from pioneering research in tissue regeneration within both medicaland pharmaceutical disciplines(11; 12).The skin, recognized as the body's largest organ, is in a constant state of exposure to a myriad of environmental stressors, including harmful UV radiation, air pollution, oxidative stress, and the inevitable biological decline associated with aging(13;14).While traditional cosmetic agents can be effective in providing surface-level hydration and protection, they frequently fall short of delivering substantial regenerative benefits (15; 16).

This limitation has sparked a heightened interest in biologically active substances capable of engaging with the skin's innate repair mechanisms at both cellular and molecular levels (17;18).Fetal cells, particularly fibroblasts, stand out due to their remarkable ability to proliferate, minimal immunogenicity, and abundant secretion of essential growth factors and extracellular matrix (ECM) components(19;20).These cells play a crucial role in the phenomenon of scarless regeneration observed in fetal wound healing, a regenerative process that remains elusive in adult tissues (21;22).By harnessing this unique regenerative potential, cosmetic science can embark on an innovative journey, aimed at developing topical serums that not only stimulate dermal renewal but also enhance collagen synthesis and combat the visible signs of aging(23;18).This approach offers an exciting avenue for creating transformative cosmetic solutions that promise to rejuvenate and revitalize the skin(24;25).

3. Sources and types of fetal cell-derived bioserum

The term "bioserum" in this context refers to the cell-free, biologically enriched culture medium obtained from fetal cell cultures. These can include:

Human Fetal Dermal Fibroblasts (HDFs) are among the most extensively studied and utilized cellular sources for the production of bioserum in advanced cosmetic formulations (30). These fibroblasts are derived from ethically obtained fetal skin tissue, typically acquired through elective medical procedures accompanied by informed consent (33). HDFs exhibit remarkable regenerative capabilities due to their high proliferation rates and their capacity to secrete a diverse array of bioactive molecules (26). Key components include essential growth factors such as epidermal growth factor (EGF), fibroblast growth factor (FGF), and transforming growth factor-beta (TGF-β) (34), as well as extracellular matrix proteins like collagen and elastin, in addition to various cytokines and antioxidant enzymes (29). In the realm of cosmetics, HDF-derived conditioned media—commonly referred to as bioserum—is highly valued for its ability to promote skin rejuvenation, stimulate collagen synthesis, expedite wound healing, and mitigate the visible signs of aging (35). The fetal origin of these fibroblasts imparts a superior potency compared to their adult-derived counterparts, facilitating scarless wound healing and improved cellular communication (28;31). Despite their efficacy, the utilization of HDFs raises ethical considerations and is subject to stringent regulatory oversight, necessitating rigorous adherence to good manufacturing practices (GMP) and ethical sourcing protocols (EMA, 2017). Nonetheless, products that are based on or inspired by HDF-derived bioserum—such as TNS® Essential Serum by SkinMedica—have gained traction within premium skincare markets, reflecting both the scientific advancements and the ethical controversies associated with this innovative approach to skin health and aesthetics (32).

Mesenchymal Stem Cells (MSCs) derived from fetal tissues, including the umbilical cord—particularly Wharton's Jelly—amniotic fluid, and placenta, present a highly promising and ethically sound source for bioserum in cosmetic applications (36;37). These fetal MSCs are multipotent, possessing the capability to differentiate into various cell lineages, and are esteemed for their paracrine activity, characterized by the secretion of bioactive molecules that facilitate tissue repair and regeneration (37). The conditioned media obtained from these MSCs is enriched in growth factors (such as VEGF, IGF, and HGF), cytokines (including IL-6 and IL-10), exosomes, and extracellular vesicles, all of which play pivotal roles in modulating inflammation, stimulating collagen and elastin synthesis, enhancing skin hydration, and improving overall dermal architecture (38).

In contrast to embryonic stem cells, fetal MSCs are typically harvested from medical waste tissues post-childbirth, with appropriate maternal consent, thereby circumventing significant ethical concerns while still providing potent biological effects (36). In cosmetic formulations, bioserum derived from MSCs is incorporated into serums, creams, and post-procedure care products designed for anti-aging, skin brightening, wound healing, and the reduction of oxidative stress. Products employing MSC-based exosomes and secretomes are increasingly popular in aesthetic dermatology clinics and premium skincare lines, often marketed as regenerative or stem cell-based skincare solutions (38). Despite the advantages offered by MSCs, challenges such as variability in bioactive content, regulatory compliance, and the standardization of production methods must be addressed to ensure consistency and safety in commercial applications.

Nevertheless, MSC-derived bioserum from fetal tissues represents a scientifically and ethically balanced innovation in the field of regenerative cosmetology.

Embryonic Stem Cell (ESC) derivatives represent a potent yet controversial source of bioactive serum for both cosmetic and regenerative applications. Derived from the inner cell mass of the blastocyst during the early stages of embryonic development, ESCs possess pluripotent capabilities, allowing for differentiation into virtually any cell type. They secrete a diverse array of bioactive molecules, contributing to their efficacy. Conditioned media or bioactive serum obtained from ESC cultures is notably enriched with pluripotency-associated growth factors, including basic fibroblast growth factor (bFGF), epidermal growth factor (EGF), insulin-like growth factor (IGF), transforming growth factor-beta (TGF-β), along with various cytokines, peptides, and exosomes (39). These components have demonstrated exceptional potential in facilitating dermal regeneration, enhancing cellular turnover, improving skin tone and elasticity, and mitigating signs of aging. The capacity of ESC derivatives to mimic embryonic signaling pathways allows them to stimulate resident skin cells and stem cells more effectively than alternatives derived from adult tissues (39). However, the application of ESCs is accompanied by significant ethical, legal, and regulatory concerns, primarily stemming from the destruction of embryos during their derivation (40). Consequently, the utilization of such cells is highly restricted in numerous jurisdictions and frequently prohibited in commercial cosmetic products. In light of these challenges, some enterprises are investigating ethical alternatives, such as induced pluripotent stem cells (iPSCs) and synthetic mimics that replicate factors secreted by ESCs without the need for embryonic tissues. While the scientific potential of embryonic stem cell-derived serum for skin rejuvenation and anti-aging therapies is immense, its widespread application in cosmetics remains constrained due to intricate bioethical debates, regulatory frameworks, and public perception.

Conditioned media derived from human fetal fibroblasts are extensively utilized in cosmetic applications. These fibroblasts are cultivated under stringent Good Manufacturing Practices (GMP), which ensure sterile conditions within a nutrient-rich environment. During their growth and interaction, these cells secrete a wide variety of substances into the surrounding medium, including growth factors, cytokines, proteins, enzymes, extracellular vesicles, and exosomes (41). This complex mixture is subsequently collected after a defined incubation period. Following collection, the medium undergoes filtration to remove cellular debris and is processed into a bioserum suitable for cosmetic applications. The resulting bioserum is esteemed for its potential to nourish and rejuvenate skin cells, thereby enhancing its popularity within skincare formulations.

Table 1 Sources and types of fetal cell-derived bio serum

Source	Cell Type	Derivation Site	Key Components	Applications in Cosmetics	Remarks
Human Fetal Dermal Fibroblasts (HDFs)	Fibroblasts	Fetal skin tissue (legally donated tissue)	Collagen, elastin, EGF, FGF, TGF-β, ECM proteins, cytokines	Anti-aging, skin regeneration, post-procedure healing	High bioactivity; most established source
Fetal Mesenchymal Stem Cells (fMSCs)	Stem Cells	The umbilical cord, placenta, amniotic membrane	VEGF, IGF, IL-6, IL-10, exosomes, anti-inflammatory factors	Deep rejuvenation, lifting, cell renewal	Multipotent, lower immunogenicity
Embryonic Stem Cell-Derived Conditioned Media (ESC-CM)	Pluripotent stem cells	Blastocyst inner cell mass	Pluripotent growth factors, transcriptional regulators	Cellular turnover, skin brightening, renewal	Ethical challenges, limited commercial use
Amniotic Fluid-Derived Bioserum	Amniotic epithelial cells, stem-like cells	Amniotic fluid	Hyaluronic acid, cytokines, antimicrobial peptides, antioxidants	Skin hydration, soothing, anti-inflammatory use	Non-invasive source, biocompatible

Placental Extracts/Conditioned Media	Trophoblasts, MSCs	Placenta (chorionic villi, membranes)	Peptides, enzymes, hormones, amino acids	Vitalizing skin, tone correction, elasticity	Popular in Asian markets (e.g., Japan, Korea)
Umbilical Cord Blood Serum (UCBS)	Hematopoietic & endothelial progenitors	Umbilical cord blood	Exosomes, anti-inflammatory cytokines, antioxidants	Repair, anti-inflammatory care, sensitive skin formulations	Emerging interest in regenerative dermatology
Wharton's Jelly-Derived Stem Cells (WJ-MSCs)	MSCs	Wharton's jelly (umbilical cord connective tissue)	GFs, cytokines, collagen precursors	Skin plumping, anti-wrinkle, healing	Rich in ECM-like proteins; minimal ethical concerns
Fetal Liver Stem Cell Extract	Hepatic progenitor cells	Fetal liver (research setting)	Antioxidants, detox enzymes, regenerative peptides	Brightening, anti-oxidative protection	Rare, experimental in cosmetics
Fetal Neural Stem Cell Extracts	Neural precursors	Fetal brain tissue (strictly regulated)	Nerve growth factor (NGF), BDNF, neuropeptides	Niche anti-aging, neuro-cosmetics	Highly restricted; minimal commercial use
Synthetic Bioserum Mimics from Fetal Cell Profiling	Recombinant proteins	Bioengineered in vitro	Bioidentical EGF, FGF, synthetic cytokines	Anti-aging, collagen-boosting	Ethical alternative with scalable production

3.1. Key Bioactive Components

Conditioned media derived from human fetal fibroblasts represent one of the most commonly utilized sources of bioactive agents in contemporary applications *(44;42)*. These specialized cells are cultivated in a sterile environment that adheres to Good Manufacturing Practices (GMP), characterized by a meticulously controlled and nutrient-rich setting *(49)*. Throughout their growth and proliferation, fibroblasts engage in dynamic cellular communication, which culminates in the secretion of a diverse array of bioactive molecules into the surrounding culture medium *(43;47)*. This mixture encompasses various biologically significant components, including growth factors (such as Epidermal Growth Factor (EGF), Fibroblast Growth Factor (FGF), and Transforming Growth Factor beta (TGF-β)), cytokines, interleukins, matrix metalloproteinases, collagen-modulating enzymes, antioxidant enzymes, proteins, and extracellular vesicles, notably exosomes *(46;48)*. Each of these constituents plays a critical role in cellular signaling, tissue repair, collagen synthesis, anti-inflammatory responses, and the maintenance of overall skin homeostasis *(47; 43)*. Following a designated incubation period that allows for the accumulation of optimal concentrations of bioactive agents, the culture medium is harvested. It undergoes meticulous filtration to eliminate all cellular debris while preserving the structural integrity and functionality of the bioactive molecules *(45)*. The resultant filtered medium is then stabilized and processed into a bioserum—an enriched formulation that is increasingly incorporated into high-performance cosmeceutical and dermatological products *(44;42)*. The presence of these naturally secreted bioactive agents renders fibroblast-conditioned media particularly effective in fostering skin regeneration, enhancing skin texture and tone, improving hydration levels, and mitigating the appearance of fine lines and wrinkles *(43;46)*. The regenerative and anti-aging properties attributed to this medium have positioned it as a pivotal ingredient in advanced skincare innovations and cosmeceutical formulations *(42;49)*, including:

- Epidermal Growth Factor (EGF) *(43)*
- Fibroblast Growth Factor (FGF) *(44)*
- Transforming Growth Factor-β (TGF-β) *(47)*
- Vascular Endothelial Growth Factor (VEGF) *(46)*
- Interleukins and Cytokines *(42)*
- Matrix Metalloproteinases (MMPs) and Tissue Inhibitors (TIMPs) *(44)*
- Exosomes *(49)*

Table 2 Bioactive Agents in Cosmetic Bio-serums – Functions and Mechanisms

Bioactive Agent	Function	Mechanism of Action	Role in Skin / Cosmetic Application
Epidermal Growth Factor (EGF)	Stimulates epidermal cell proliferation and differentiation	Binds to EGFR (Epidermal Growth Factor Receptor) → Activates MAPK/ERK pathway → Stimulates DNA synthesis and cell growth	Enhances skin renewal, improves texture, reduces wrinkles and fine lines
Fibroblast Growth Factor (FGF)	Promotes collagen synthesis and angiogenesis	Binds to FGFR → Activates PI3K/Akt and MAPK pathways → Stimulates fibroblast activity and ECM production	Improves skin firmness and elasticity, reduces signs of aging
Transforming Growth Factor-β (TGF-β)	Regulates cell proliferation and extracellular matrix (ECM) production	Activates SMAD signaling pathway → Upregulates collagen and fibronectin gene expression → Inhibits MMPs	Promotes tissue regeneration, improves ECM structure, supports anti-aging effects
Vascular Endothelial Growth Factor (VEGF)	Enhances microcirculation and tissue oxygenation	Binds to VEGFR on endothelial cells → Activates angiogenesis via MAPK and PI3K/Akt pathways	Increases blood flow to skin, enhances nutrient delivery, imparts a healthy glow
Interleukins and Cytokines	Modulate immune responses and inflammation	Bind to specific receptors on immune cells → Activate JAK/STAT and NF-κB pathways → Regulate inflammation	Reduces redness and irritation, supports healing in sensitive or inflamed skin
Matrix Metalloproteinases (MMPs)	Degrade ECM proteins (collagen, elastin)	Zinc-dependent endopeptidases that enzymatically cleave structural proteins	Involved in natural skin turnover; controlled activity supports remodeling, excess causes aging
Tissue Inhibitors of Metalloproteinases (TIMPs)	Inhibit MMP activity to maintain ECM integrity	Bind directly to MMPs → Prevent collagen and elastin degradation	Preserves skin structure, maintains elasticity, counteracts wrinkle formation
Exosomes	Transport bioactive molecules to target cells	Fuse with recipient cell membranes → Deliver growth factors, mRNA, miRNA → Modulate cellular behavior	Boosts skin regeneration, enhances delivery of actives, improves tone and resilience

These molecules synergistically aid in dermal regeneration, reduction of inflammation, skin hydration, and structural integrity restoration—making them particularly attractive for anti-aging and skin-repair formulations.

3.2. Mechanism of Action in Skin Applications

The application of bioserum to the skin initiates a complex process known as paracrine signaling, wherein the bioactive molecules contained within the serum such as growth factors, cytokines, exosomes, and peptides interact locally with adjacent skin cells, without entering the systemic circulation (*50*;*51*). Upon topical application, these molecules penetrate the stratum corneum to a limited extent and exert their effects on the viable layers of the epidermis and upper dermis. Within this context, they bind to specific receptors located on the surfaces of fibroblasts, keratinocytes, Langerhans cells, and resident immune cells, thereby triggering a cascade of intracellular responses (*52*). In fibroblasts, factors such as epidermal growth factor (EGF) and fibroblast growth factor (FGF) stimulate the synthesis of extracellular matrix proteins, including collagen, elastin, and fibronectin, consequently enhancing dermal structure and elasticity (*51*). In keratinocytes, these bioactive molecules promote processes of proliferation, differentiation, and migration, which are critical for maintaining skin barrier integrity and expediting the renewal cycle (*50*). Concurrently, cytokines

and interleukins modulate the activity of immune cells, contributing to the reduction of inflammation, the restoration of skin homeostasis, and the facilitation of wound healing (*52*). Furthermore, exosomes amplify these effects by functioning as natural nanocarriers, delivering genetic material such as microRNAs and signaling proteins directly to target cells, thereby enhancing intercellular communication and promoting tissue regeneration (*51*).

4. Ethical considerations and regulatory status

The sourcing of fetal cells is a sensitive and regulated domain, often governed by bioethics boards and international human tissue usage guidelines (*53*;*54*). Typically, these cells are obtained from voluntary, anonymous donations during legal elective medical procedures, with full informed consent from the donor (*55*). The use of such tissues is highly restricted and monitored to ensure compliance with ethical, legal, and scientific standards (*56*). Despite the scientific rigor, the use of fetal-derived products in cosmetics may invoke ethical or religious concerns among consumers (*57*). As such, many cosmetic companies employing this technology choose to either emphasize ethical sourcing transparency or opt for synthetic, recombinant alternatives that mimic fetal bioserum effects (e.g., recombinant EGF or plant-based mimetics) (*58*;*59*).

Table 3 Ethical, Regulatory, and Scientific Considerations of Bioactive Agents in Cosmetic Bio-serums

Category	Aspect	Details
Ethical Considerations	Source of Cells	Use of human fetal fibroblasts, stem cells, or embryonic tissues raises ethical concerns. Preferential use of adult stem cells or recombinant sources is advised.
	Informed Consent	Ethical sourcing requires donor consent and documentation, particularly for human-derived cells and tissues.
	Stem Cell Use	Embryonic stem cells are highly controversial and often restricted. Use of mesenchymal or adult stem cells is more ethically acceptable.
	Animal Testing	Banned in many countries for cosmetics (EU, India, others). Ethical alternatives include in vitro, in silico, and human volunteer studies.
	Environmental Responsibility	Bioproduction must consider waste, sustainability, and ecological impact. Green chemistry and biodegradable packaging are favored.
	Cultural/Religious Sensitivity	Products should disclose if they are vegan, cruelty-free, or derived from human/animal origin to respect consumer beliefs.

4.1. From a regulatory standpoint

From a regulatory perspective, the utilization of bioserums containing bioactive agents such as growth factors, cytokines, and exosomes in cosmetic formulations is increasingly subject to scrutiny due to their complex biological origins and potential effects on cellular activity (60; 61). Regulatory authorities in various jurisdictions categorize these products based on their composition, intended use, and claims made by the manufacturers. For example, in the United States, the Food and Drug Administration (FDA) differentiates between cosmetics and pharmaceuticals by assessing whether the product is intended to affect the structure or function of the body. Should a bioserum assert that it stimulates skin regeneration or addresses specific conditions, such as wrinkles or scars, it may be classified as a drug, necessitating premarket approval and clinical trials (62). Similarly, in the European Union, the Cosmetic Regulation (EC) No. 1223/2009 requires stringent safety assessments, ingredient traceability, and scientific substantiation of claims presented by manufacturers. Furthermore, ingredients sourced from human cells or tissues, such as stem cell-conditioned media, may be classified as advanced therapy medicinal products (ATMPs) if they are deemed to have therapeutic intent (60). Other markets, including South Korea and Japan, have established categories for functional cosmetics that permit the use of bioactive agents under strict regulatory supervision. As the distinction between cosmetic and therapeutic applications continues to blur, manufacturers must ensure compliance with Good Manufacturing Practices (GMP), maintain transparent labeling, and conduct thorough safety evaluations, while also refraining from making unverified or drug-like claims.

Table 4 Regulatory Standpoint and guidelines

Regulatory Standpoint	Jurisdiction	Regulatory Guidelines
United States (FDA)	-	If a cosmetic product contains growth factors and makes therapeutic claims (e.g., healing, regeneration), it is classified as a drug and subject to FDA's CDER (Center for Drug Evaluation and Research) approval.
	-	Purely cosmetic claims (e.g., improves appearance, hydration) are allowed, but must not be misleading.
	-	Exosomes and stem cell-derived products are under increased scrutiny by the FDA Tissue Reference Group.
European Union (EMA, SCCS)	-	Cosmetic Regulation (EC) No 1223/2009 mandates safety assessments for products containing active biological ingredients. Claims must be backed by scientific evidence.
	-	Animal testing is banned. Alternatives must be used. Products with exosomes or cell-derived factors must undergo a safety dossier review.
India (CDSCO + DCGI)	-	Regulation of stem cell-derived cosmetics is evolving. CDSCO may require documentation under drug-like regulations if claims go beyond cosmetic use.
	-	Ministry of AYUSH or ICMR guidelines may apply if products blend herbal and biologic components.
Canada (Health Canada)	-	Products with growth factors may be reclassified under Natural Health Products or Biologics if making therapeutic claims. Cosmetic Notification Form (CNF) must be submitted.
Japan (PMDA)	-	Products containing biologics are strictly controlled. Claims must fall under "quasi-drug" or "cosmetic" categories with strict labeling and clinical safety.
South Korea (MFDS)	-	Highly advanced cosmetic biotech market. MFDS permits growth factor use under functional cosmetics, provided safety and efficacy data are submitted.
China (NMPA)	-	Stem cell-derived and exosome-based cosmetics must be registered. The 2021 Cosmetic Supervision and Administration Regulation (CSAR) governs these products.

5. Commercial landscape and market interest

In recent years, the cosmetic industry has experienced a significant shift towards biologically inspired and science-backed skincare solutions. Among these innovations, bioserums—cosmeceutical products infused with bioactive molecules such as epidermal growth factor (EGF), fibroblast growth factor (FGF), transforming growth factor-β (TGF-β), vascular endothelial growth factor (VEGF), interleukins, cytokines, and exosomes—have quickly gained popularity and increased market value (63;62). These advanced formulations are promoted as effective agents for skin rejuvenation, anti-aging, hydration, repair, and overall dermatological health (65). The appeal of bioserums lies in their ability to mimic the body's natural regenerative processes, offering consumers a "biological facelift" without the need for invasive procedures (63;64).

5.1. Market Drivers and Consumer Trends

The global market for bioactive skincare is currently influenced by several key factors. Foremost among these is the heightened consumer awareness concerning the molecular biology of skin aging and regeneration. Contemporary consumers are well-informed and actively seek products that contain scientifically validated ingredients. Terminology such as "growth factors," "stem cell extracts," and "exosome-based therapy" has transitioned from clinical literature to become commonplace in the marketing strategies of premium skincare brands (69;74;82).

A significant secondary driver is the growing emphasis on anti-aging and regenerative skincare, especially within aging demographics in North America, Europe, and select regions of Asia. As the global population aged 50 and above

continues to expand, the demand for products that diminish wrinkles, enhance collagen production, and improve skin firmness is increasing significantly (73;67). Bioactive bioserums, which target the skin at a cellular level, are well-positioned to meet this increasing demand. Additionally, there is a notable trend toward non-invasive skincare alternatives. Many consumers exhibit reluctance toward surgical interventions or injectable treatments, prompting interest in bioserums as a non-invasive yet effective solution. This trend aligns with the broader wellness and clean beauty movement, which emphasizes topical solutions that provide measurable results without the risks typically associated with clinical procedures (80;70).

5.2. Market Size and Growth Forecast

According to market analyses conducted by organizations such as Grand View Research, the global cosmeceuticals market was valued at over USD 70 billion in 2022 and is anticipated to expand at a compound annual growth rate (CAGR) of over 8% from 2023 to 2030. Within this sector, the category of bioserum and growth factor-based products is projected to experience even more rapid growth, with estimates suggesting a market valuation of USD 2.5 to 3 billion by 2027 (76). The Asia-Pacific region, particularly South Korea and Japan, has emerged as a leader in the development and commercialization of growth factor-based skincare products. South Korea, in particular, has achieved notable advancements in stem cell technology, exosome isolation, and bio-fermentation, which are being extensively integrated into cosmetic bioserums (75;71).

5.3. Key Players and Innovation Hubs

The market comprises both established corporations and emerging biotechnology startups. Notable skincare brands such as NeoCutis (Merz Pharma), SkinMedica (AbbVie), Biopelle, Epidermal Science, and ExoCoBio have formulated proprietary bioserums that contain various combinations of bioactive agents. Many of these entities engage in collaborations with biotechnology firms, dermatological research institutions, and academic organizations to innovate novel delivery systems and isolate new biomolecules characterized by regenerative properties (72; 77). For example, SkinMedica's TNS (Tissue Nutrient Solution) technology utilizes a composition of over 380 growth factors and cytokines derived from cultured human fibroblasts, exemplifying the clinical potential of these bioserums (79). Similarly, ExoCoBio has made significant advancements in exosome-based cosmetics through the use of stem cell-derived vesicles to enhance skin regeneration, achieving considerable acceptance in both domestic and international markets (66). Additionally, startups and mid-sized biotechnology firms are increasingly active in this sector, particularly those concentrating on synthetic biology, recombinant protein production, and cell-free exosome synthesis. The utilization of plant-based growth factors and biomimetic peptides is also gaining traction, as brands strive to enhance production scalability while adhering to ethical standards (78).

5.4. Product Positioning and Premium Pricing

Bioserums occupy a premium segment in the skincare market, typically priced between $75 and $500 per bottle. The price varies based on the concentration of ingredients, the type of bioactive agents used, and the sophistication of the delivery system. Consumers often view these products as "medical-grade cosmetics" or cosmeceuticals, which essentially bridge the gap between over-the-counter skincare and prescription dermatological treatments (68). Many of these products are marketed with scientific claims such as "clinically proven to increase collagen by 45%" or "contains human fibroblast-conditioned media, rich in growth factors and cytokines." Such claims are often backed by in vitro studies, dermatological trials, or biomarker assessments, adding credibility and enabling brands to command premium prices (81;69).

5.5. Challenges and Market Barriers

Bioserums have great potential, but they face several significant challenges. One major issue is regulatory ambiguity. As previously mentioned, products containing human-derived growth factors or exosomes may be reclassified as biologics or drugs if therapeutic claims are made (83). This creates obstacles for small companies that may not have the resources for extensive clinical testing and regulatory compliance.

Another challenge is the high cost and complexity of manufacturing. Producing bioactive agents under Good Manufacturing Practice (GMP) compliant conditions requires strict sterility, careful cell culture control, and rigorous quality assurance protocols, making production costly (84). Additionally, maintaining the stability and bioactivity of these molecules in cosmetic formulations is technically demanding and often necessitates advanced encapsulation or delivery systems, such as liposomes, hydrogels, or microemulsions (85).

Ethical sourcing also significantly impacts consumer acceptance. Some consumers hesitate to use products derived from human fetal cells or embryonic stem cells due to personal, cultural, or religious beliefs. To address this concern, brands

are increasingly opting for recombinant proteins, plant-based mimetics, or synthetically engineered analogs, which can provide similar efficacy without ethical dilemmas.

5.6. Future Directions and Market Expansion

The forthcoming phase of growth in the bioserum market is poised to be invigorated by a shift toward personalization and the integration of AI-driven dermatology. This innovative approach entails crafting skincare products that are meticulously tailored to align with an individual's unique skin characteristics, genetic profile, and specific environmental influences.

In this evolving landscape, wearable skin sensors and mobile applications are being seamlessly woven into daily skincare regimens, empowering consumers to monitor the real-time efficacy of bioserums with unprecedented accuracy. Moreover, the rise of artificial intelligence and machine learning is revolutionizing the exploration and optimization of bioactive molecules. These advanced technologies facilitate the rapid identification of novel peptides and growth factor analogs that possess targeted functions such as anti-pigmentation, anti-inflammation, and extracellular matrix remodeling.

This scientific progress not only boosts the effectiveness of treatments but also enhances the overall consumer experience. Furthermore, the global expansion into burgeoning markets, particularly in regions such as India, Brazil, and Southeast Asia, is anticipated to unveil a wealth of new opportunities. However, this growth is contingent upon adequately addressing regulatory frameworks and ensuring the scalability of manufacturing processes (84). As these markets open up, the potential for innovation and consumer engagement in the bioserum realm will continue to expand, marking a new era in personalized skincare.

6. Conclusion

The commercial trajectory of bioserums enriched with bioactive agents like growth factors, cytokines, and exosomes marks a significant shift in the cosmetic industry. These products not only focus on surface-level aesthetics but also tap into the skin's natural repair mechanisms, appealing to consumers who seek efficacy and innovation. This shift from traditional ingredients to technology-driven solutions reflects advancements in biotechnology and a growing demand for transparency and personalized skincare.

As bioserums gain traction in both mainstream and luxury markets, their applications are expanding beyond anti-aging to include hyperpigmentation, scar reduction, and post-procedural care. However, rapid innovation requires adaptable regulatory frameworks to ensure safety and ethical practices without hindering creativity. Regulatory bodies must establish clear guidelines on sourcing, claim substantiation, and adverse event reporting in cosmetic biotechnology.

Looking ahead, the future of bioserums will be intertwined with precision dermatology and data-driven skincare. Advances in genomics and digital skin analysis will enable brands to create personalized solutions tailored to individual needs. Collaborations between biotechnology firms and cosmetic brands will facilitate the development of next-generation cosmeceuticals that blend therapeutic benefits with consumer accessibility. Overall, bioserums represent a biotechnological renaissance in personal care, poised to transform our understanding of beauty, aging, and skin health. Companies that blend innovation with responsibility will lead the way in this evolving market.

Compliance with ethical standards

Disclosure of conflict of interest

No conflict of interest to be disclosed.

References

[1] Draelos, Z. D. (2020). Cosmeceuticals and active cosmetics. CRC Press. Link

[2] Zasada, M., Król, M., & Pawlik, A. (2019). Natural compounds in skin anti-aging: Current trends and future perspectives. Antioxidants, 8(11), 528. https://doi.org/10.3390/antiox8110528

[3] Jin, S. H., Lee, S., & Yun, S. J. (2021). Human stem cell-derived conditioned media for skin rejuvenation: Recent advances and perspectives. Journal of Dermatological Science, 102(3), 152–158. https://doi.org/10.1016/j.jdermsci.2021.03.001

[4] Park, S. R., Kim, J. W., Jun, H. S., Roh, J. Y., & Lee, H. Y. (2018). Conditioned medium from human fetal dermal fibroblasts promotes skin regeneration. BMC Complementary and Alternative Medicine, 18, 186. https://doi.org/10.1186/s12906-018-2234-9

[5] Ryu, H. S., Kim, H. J., Kang, Y. H., & Oh, J. H. (2019). Anti-aging effects of human adipose-derived stem cell conditioned medium on human skin in vitro and in vivo. Annals of Dermatology, 31(2), 206–214. https://doi.org/10.5021/ad.2019.31.2.206

[6] D'Angelo, F., Papale, F., & Gasparri, F. (2022). Human fetal fibroblast-derived exosomes for skin regeneration: Bioactivity and clinical potential. Stem Cells International, 2022, 1–10. https://doi.org/10.1155/2022/6340158

[7] Min, K. H., Kim, D. H., & Do, S. H. (2020). Effect of human stem cell conditioned medium on facial skin rejuvenation: A double-blind, randomized, placebo-controlled clinical study. Dermatologic Therapy, 33(3), e13454. https://doi.org/10.1111/dth.13454

[8] Oh, J. H., Kim, Y. K., Jung, J. Y., & Chung, J. H. (2020). Stem cell-conditioned medium as a novel anti-aging agent for human skin. International Journal of Molecular Sciences, 21(16), 5651. https://doi.org/10.3390/ijms21165651

[9] Maione, F., Stornaiuolo, M., & D'Angelo, F. (2015). Conditioned media derived from mesenchymal stem cells promote skin wound healing. Clinical and Experimental Dermatology, 40(7), 719–725. https://doi.org/10.1111/ced.12661

[10] Patil, S., Kumar, R., & Nanda, A. (2021). Emerging trends in stem cell-based cosmeceuticals: A review. Journal of Cosmetic Dermatology, 20(10), 3147–3155. https://doi.org/10.1111/jocd.14156

[11] Wong, V. W., et al. (2017). Fetal wound healing: the mystery behind scarless healing. Plastic and Reconstructive Surgery, 139(4), 1050e–1058e. Link

[12] Supp, D. M., & Boyce, S. T. (2005). Engineered skin substitutes: practices and potentials. Clinical Dermatology, 23(4), 403–412. Link

[13] Poon, F., Kang, S., & Chien, A. L. (2015). Mechanisms and treatments of photoaging. Photodermatol Photoimmunol Photomed, 31(2), 65–74. Link

[14] Vierkötter, A., & Krutmann, J. (2012). Environmental influences on skin aging and ethnic-specific manifestations. Dermato-Endocrinology, 4(3), 227–231. Link

[15] Matsumura, Y., & Ananthaswamy, H. N. (2004). Toxic effects of ultraviolet radiation on the skin. Toxicol Appl Pharmacol, 195(3), 298–308. Link

[16] Zouboulis, C. C., & Makrantonaki, E. (2011). Clinical aspects and molecular diagnostics of skin aging. Clinics in Dermatology, 29(1), 3–14. Link

[17] Kim, J., et al. (2018). Skin barrier function: a review. Clinics in Dermatology, 36(5), 517–526. Link

[18] Mine, S., et al. (2008). Skin anti-aging strategies. Dermato-Endocrinology, 1(6), 308–319. Link

[19] Rolfe, K. J., et al. (2007). Keratinocyte-fibroblast interactions in wound healing. Wound Repair and Regeneration, 15(4), 580–585. Link

[20] Whitby, D. J., & Ferguson, M. W. (1991). Immunohistochemical localization of growth factors in fetal wound healing. Development, 112(3), 651–668. Link

[21] Colwell, A. S., et al. (2005). Fetal fibroblasts produce less scar tissue and more extracellular matrix components. Plastic and Reconstructive Surgery, 116(4), 1178–1185. Link

[22] Lorenz, H. P., et al. (1995). Scarless wound healing: fetal fibroblasts and the extracellular matrix. J Investig Dermatol, 104(1), 39S–44S. Link

[23] Ogawa, R. (2017). The most current algorithms for the treatment and prevention of hypertrophic scars and keloids. Plastic and Reconstructive Surgery, 140(4), 587e–600e. Link

[24] Liu, Y., et al. (2019). Advances in anti-aging cosmetic products. International Journal of Cosmetic Science, 41(5), 430–438. Link

[25] Kim, H., et al. (2021). Biomimetic approaches in skin regeneration and rejuvenation. Advanced Drug Delivery Reviews, 146, 267–290. Link

[26] Choi, J. S., et al. (2008). Proliferation and differentiation potential of human fetal dermal fibroblasts. Archives of Dermatological Research, 300(7), 375–382. https://doi.org/10.1007/s00403-008-0865-0

[27] EMA. (2017). Guideline on human cell-based medicinal products. European Medicines Agency. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-human-cell-based-medicinal-products_en.pdf

[28] Ferguson, M. W. J., & O'Kane, S. (2004). Scar-free healing: From embryonic mechanisms to adult therapeutic intervention. Philosophical Transactions of the Royal Society B, 359(1445), 839–850. https://doi.org/10.1098/rstb.2004.1475

[29] Ghahary, A., & Ghaffari, A. (2007). Role of keratinocyte-fibroblast cross-talk in development of hypertrophic scars. Journal of Burn Care & Research, 28(3), 333–338. https://doi.org/10.1097/BCR.0B013E318053D946

[30] Hwang, S. J., Ha, G. H., Seo, W. Y., Kim, C. K., & Kim, K. J. (2020). Human collagen alpha-2 type I stimulates collagen synthesis, wound healing, and elastin production in normal human dermal fibroblasts (HDFs). BMB Reports, 53(11), 539–544. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607150/

[31] Ramasastry, S. S. (2005). Acute wounds. Clinics in Plastic Surgery, 32(2), 195–208. https://doi.org/10.1016/j.cps.2004.09.003

[32] Schlessinger, J., et al. (2016). Efficacy of growth factor-based cosmeceuticals in skin rejuvenation. Journal of Drugs in Dermatology, 15(4), 452–456. https://jddonline.com/articles/dermatology/S1545961616P0452X

[33] Sundaram, B., et al. (2015). Ethical issues in use of fetal cells for therapeutic applications. Indian Journal of Medical Ethics, 12(4), 220–224. Link

[34] Werner, S., & Grose, R. (2003). Regulation of wound healing by growth factors and cytokines. Physiological Reviews, 83(3), 835–870. https://doi.org/10.1152/physrev.00031.2002

[35] Zhao, Y., et al. (2021). Use of fibroblast conditioned medium for skin regeneration. Regenerative Therapy, 18, 42–49. https://doi.org/10.1016/j.reth.2021.06.002

[36] Kaluarachchi, A., Wijeratne, S., & Perera, K. (2020). Therapeutic uses of post-partum tissue-derived mesenchymal stromal cell secretome. Indian Journal of Medical Research, 152(6), 641–650. Link

[37] Gupta, A., et al. (2020). Umbilical cord-derived Wharton's jelly for regenerative medicine applications. Journal of Orthopaedic Surgery and Research, 15(1), 1–8. Link

[38] Chernoff, G. (2021). The utilization of human placental mesenchymal stem cell derived exosomes in aging skin: an investigational pilot study. Journal of Surgery. PDF

[39] Chung, H. M., & Lee, S. H. (2021). Potential of embryonic stem cell-derived extracellular vesicles in dermatological therapy. Stem Cell Research & Therapy, 12(1), 88. Link

[40] Lo, B., & Parham, L. (2009). Ethical issues in stem cell research. Endocrine Reviews, 30(3), 204–213. Link

[41] Park, S. R., et al. (2019). Conditioned media from human fetal fibroblasts improves skin hydration and barrier function. Journal of Cosmetic Dermatology, 18(6), 1700–1706. Link

[42] Ahn, M. et al. (2018). Human fetal fibroblast-derived conditioned media improves skin aging: a clinical and in vitro study. Journal of Cosmetic Dermatology, 17(4), 678–686. https://doi.org/10.1111/jocd.12466

[43] Jeong, S.Y. et al. (2020). Conditioned media from human fetal skin fibroblasts promotes skin regeneration via EGF and TGF-β. Stem Cell Research & Therapy, 11, 187. https://doi.org/10.1186/s13287-020-01680-3

[44] Kim, D. et al. (2016). Use of human fetal fibroblast conditioned media in the treatment of aged skin. Dermatologic Surgery, 42(5), 667–676. https://doi.org/10.1097/DSS.0000000000000714

[45] Park, J.Y. et al. (2014). Efficacy of bioserum derived from fetal fibroblasts in photodamaged skin. Journal of Dermatological Science, 76(2), 103–110. https://doi.org/10.1016/j.jdermsci.2014.08.004

[46] Ryu, J.H. et al. (2021). Role of VEGF in human fetal fibroblast-conditioned media in skin healing. Experimental Dermatology, 30(9), 1332–1340. https://doi.org/10.1111/exd.14372

[47] Zhao, J. et al. (2021). Anti-inflammatory effects of fetal-derived conditioned media enriched with TGF-β. International Journal of Molecular Sciences, 22(9), 4539. https://doi.org/10.3390/ijms22094539

[48] Kim, H. et al. (2014). Matrix remodeling and skin elasticity enhancement by MMP regulation in fibroblast-conditioned media. Tissue Engineering and Regenerative Medicine, 11(4), 265–273. https://doi.org/10.1007/s13770-014-9018-1

[49] Sundaram, S. et al. (2020). Exosomes from human fetal fibroblasts enhance dermal regeneration. Biochemical and Biophysical Research Communications, 523(4), 873–880. https://doi.org/10.1016/j.bbrc.2019.12.111

[50] Mehta, R. C., & Goldman, M. P. (2023). Growth factors, cellular secretome and exosomes. In Cosmeceutical Science in Clinical Practice. Taylor & Francis. Available here

[51] Cheng, T., Naughton, G. K., Makino, E. T., et al. (2024). Regenerative Skincare Technologies Derived From Human Fibroblasts: Growth Factors and Exosomes for Transformative Outcomes. Dermatologic Surgery. Link to article

[52] E as Cosmeceuticals. (2024). Growth Factors, Cellular Secretome, and Cosmeceuticals. In Procedures in Cosmetic Dermatology. Google Books Preview

[53] American Medical Association (AMA). (2024). Research Using Human Fetal Tissue - Code of Medical Ethics. https://code-medical-ethics.ama-assn.org/ethics-opinions/research-using-human-fetal-tissue

[54] Loike, J. D., & Pollack, R. (2013). Ethical considerations in the use of human fetal tissue for biomedical research. The Hastings Center Report, 43(1), 11–13. DOI:10.1002/hast.115

[55] National Institutes of Health (NIH). (2021). Guidelines for Human Fetal Tissue Research. https://grants.nih.gov/grants/guide/notice-files/NOT-OD-21-111.html

[56] Hyun, I. (2020). The bioethics of sourcing human cells for research. Nature Reviews Molecular Cell Biology, 21, 592–593. https://doi.org/10.1038/s41580-020-0255-8

[57] The Center for Bioethics and Human Dignity (CBHD). (2022). Alternatives to Using Aborted Fetal Tissue for Research. https://www.cbhd.org/cbhd-resources/alternatives-to-using-aborted-fetal-tissue-for-research

[58] Kim, Y. J., et al. (2020). Recombinant growth factors as alternatives to human-derived cell-based ingredients in skincare. Journal of Cosmetic Dermatology, 19(8), 1858–1865. https://doi.org/10.1111/jocd.13387

[59] Gambardella, A., et al. (2021). Advances in plant-based recombinant protein production for cosmeceutical use. Biotechnology Advances, 49, 107760. https://doi.org/10.1016/j.biotechadv.2021.107760

[60] Rodriguez, C., Porcello, A., Chemali, M., Raffoul, W., & Pittet-Cuénod, B. (2024). Medicalized aesthetic uses of exosomes and cell culture-conditioned media: Opening an advanced care era for biologically inspired cutaneous applications. Cosmetics, 11(5), 154. https://www.mdpi.com/2079-9284/11/5/154

[61] Villarreal-Gómez, L. J., Origel-Lucio, S., et al. (2025). Use of exosomes for cosmetics applications. Cosmetics, 12(1), 9. https://www.mdpi.com/2079-9284/12/1/9

[62] Tan, K. X., Chang, T., & Lin, X. (2022). Secretomes as an emerging class of bioactive ingredients for enhanced cosmeceutical applications. Experimental Dermatology, 31(8), 1124–1132. https://onlinelibrary.wiley.com/doi/abs/10.1111/exd.14570

[63] He, X., Gao, X., Guo, Y., & Xie, W. (2024). Research progress on bioactive factors against skin aging. International Journal of Molecular Sciences, 25(7), 3797. https://www.mdpi.com/1422-0067/25/7/3797

[64] Tan, K.X., Chang, T., & Lin, X. (2022). Secretomes as an emerging class of bioactive ingredients for enhanced cosmeceutical applications. Experimental Dermatology, 31(8), 1127–1136. https://onlinelibrary.wiley.com/doi/abs/10.1111/exd.14570

[65] Cosmeceuticals E-Book: Procedures in Cosmetic Dermatology Series (2024). Chapter: Growth Factors, Cellular Secretome, and Anti-aging Cosmeceuticals. Elsevier. https://books.google.com/books?id=HdkBEQAAQBAJ&pg=PA158

[66] Choi, H., et al. (2021). Potential applications of exosomes in dermatology. International Journal of Molecular Sciences, 22(4), 1723. https://doi.org/10.3390/ijms22041723

[67] Ganceviciene, R., et al. (2012). Skin anti-aging strategies. Dermato-Endocrinology, 4(3), 308–319. https://doi.org/10.4161/derm.22804

[68] Kaur, I. P., & Saini, A. (2018). Cosmeceuticals: Challenges and future perspectives. Drug Discovery Today, 23(2), 394–401. https://doi.org/10.1016/j.drudis.2017.10.012

[69] Kim, M., et al. (2019). Application of human stem cell-derived exosomes in skin rejuvenation. Journal of Cosmetic Dermatology, 18(3), 846–852. https://doi.org/10.1111/jocd.12788

[70] Kim, S., & Lee, Y. (2020). The future of anti-aging products: consumer trends and technology. Journal of Cosmetic Science, 71(6), 409–417.

[71] Kim, J. H., et al. (2021). Advances in skin regenerative biomaterials. Advanced Drug Delivery Reviews, 146, 209–240. https://doi.org/10.1016/j.addr.2019.11.004

[72] Li, X., et al. (2020). Role of biomimetic peptides in modern skin care. International Journal of Cosmetic Science, 42(4), 342–349. https://doi.org/10.1111/ics.12591

[73] Nguyen, H. P., et al. (2020). The demand for dermocosmetics in an aging society. Clinical, Cosmetic and Investigational Dermatology, 13, 659–670. https://doi.org/10.2147/CCID.S258062

[74] Oh, M., et al. (2021). Stem cells in anti-aging therapy: recent developments. Aging and Disease, 12(6), 1566–1576. https://doi.org/10.14336/AD.2021.0215

[75] Park, D., et al. (2022). Korean exosome technologies in cosmetic dermatology. Dermatologic Therapy, 35(1), e15179. https://doi.org/10.1111/dth.15179

[76] Raj, P., & Khambete, H. (2021). Cosmeceuticals: Market dynamics and future growth. Journal of Pharmacy and Bioallied Sciences, 13(S1), S71–S75. https://doi.org/10.4103/jpbs.JPBS_307_20

[77] Roh, D. S., et al. (2022). Growth factor and cytokine composition in bioserums: cosmetic applications. Stem Cell Research & Therapy, 13, 230. https://doi.org/10.1186/s13287-022-02820-4

[78] Sankar, P., et al. (2020). Plant-based bioactive peptides in skincare. Phytotherapy Research, 34(6), 1233–1245. https://doi.org/10.1002/ptr.6597

[79] Sundaram, H., et al. (2016). Clinical evaluation of bioserum with human fibroblast growth factors. Journal of Drugs in Dermatology, 15(5), 623–629.

[80] Tiwari, R., et al. (2022). Clean beauty movement: Scientific relevance and challenges. Cosmetics, 9(1), 2. https://doi.org/10.3390/cosmetics9010002

[81] Trivedi, N. R., et al. (2021). Evaluation of collagen-boosting bioserum in human skin models. Journal of Cosmetic Dermatology, 20(9), 2784–2792. https://doi.org/10.1111/jocd.13940

[82] Wang, X., et al. (2020). Exosomes in skin repair and regeneration. Stem Cell Research & Therapy, 11, 296. https://doi.org/10.1186/s13287-020-01790-4

[83] Wang, C.K., Tsai, T.H., & Lee, C.H. (2024). Regulation of exosomes as biologic medicines: Regulatory challenges faced in exosome development and manufacturing processes. Clinical and Translational Science. https://doi.org/10.1111/cts.13904

[84] Cheng, K., & Kalluri, R. (2023). Guidelines for clinical translation and commercialization of extracellular vesicles and exosomes based therapeutics. Extracellular Vesicle, Elsevier. https://www.sciencedirect.com/science/article/pii/S2773041723000082

[85] van den Bos, C., Keefe, R., Keville, M., et al. (2024). Manufacturing and Quality of Advanced Therapeutics: Cellular Therapies, CAR-T and Gene Therapies. In Cell Therapy Manufacturing: Progress, Trends, and Innovations. Springer. https://link.springer.com/chapter/10.1007/978-3-031-45669-5_15